Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$134.15
pos +3.30
+2.50%
Today's Range: 130.39 - 134.66 | CELG Avg Daily Volume: 3,902,400
Last Update: 06/28/17 - 3:07 PM EDT
Volume: 3,798,860
YTD Performance: 13.05%
Open: $131.41
Previous Close: $130.85
52 Week Range: $92.98 - $137.54
Oustanding Shares: 780,824,335
Market Cap: 104,513,337,240
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 13 15 15
Moderate Buy 0 0 0 0
Hold 2 3 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.25 1.38 1.24 1.24
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 50.32
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
50.32 50.30 30.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.80% 37.95% 50.75%
GROWTH 12 Mo 3 Yr CAGR
Revenue 21.30 0.70 0.20
Net Income 24.80 0.40 0.11
EPS 28.40 0.50 0.14
Earnings for CELG:
EBITDA 3.71B
Revenue 11.23B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.61 $1.70 $6.62 $8.22
Number of Analysts 7 7 8 4
High Estimate $1.67 $1.77 $6.77 $8.44
Low Estimate $1.54 $1.67 $6.49 $7.91
Prior Year $1.28 $1.39 $5.18 $6.62
Growth Rate (Year over Year) 26.12% 22.51% 27.78% 24.19%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

My Takeaways and Observations Real Money Pro($)

"I'd unravel every riddle for any individ'le, In trouble or in pain. With the thoughts I'd be thinkin' I could be another Lin…
It just isn't as useful or descriptive right now.
The sector decisively has pushed through upward resistance levels in place for many months.

The Market Advance Narrows Real Money Pro($)

"For a day where the S&P was essentially flat, there was a lot going on beneath the surface.
Down-and-out stocks have become toxic.

Celgene Bucks Biotech Trend Real Money Pro($)

Stocks wrapped up a directionless day of trading near even. Despite the turmoil in D.C., volatility in the market remains remarkably low. Celgene (CELG) bucked the slightly downward trend in biotech as Leerink Swann reiterated its Buy rating. Oppenheimer did the same thing a few days ago. Celgene is one of best growth plays in the market, but it has not done much in two years despite 60% earnings growth over the past 2½ years.
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Takeaways and Observations Real Money Pro($)

  Top 10 Reasons the Lambs May Be Sheared ... or Slaughtered.    Stated simply, I see a trend change. &nbs…
Tech meltdown provides an opportunity for rotation into undervalued sectors.
We really want to shake out the weak hands here.

Columnist Conversations

Nice bump for X today. Stock is up over 5% and is headed for its best close of the month. Still basing but imp...
The Semiconductor sector (SMH) is rebounding off its 50-day moving average, and I'm picking at a few different...
we like this chart setup here and with earnings Thurs, we'll take a position. BOUGHT STZ AUG 185 CALL AT 6...
Warren Buffett's recent purchase of Store Capital Corp. (STOR), a real estate investment trust (REIT), seems t...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.